Royalty Report: Drugs, Vaccine, Therapeutic – Collection: 230788

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 12

Primary Industries

  • Drugs
  • Vaccine
  • Therapeutic
  • Disease
  • Cancer
  • HIV / AIDs
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 230788

License Grant
Licensor grants an exclusive license in the Territory, including the right to grant sublicenses, to manufacture, use, sell, offer for sale, and import Products under all its right, title and interest in the Patent Rights.
License Property
Product means any animal vaccine or therapeutic agent the manufacture, use, sale, offer for sale or import of which would infringe any Valid Claim within Patent Rights in the absence of a license.

Food Safety Product means a Product to eliminate or reduce organisms associated with food borne disease in livestock.

The licensed property include patents for Immunogenic compositions comprising avirulent derivatives of Salmonella typhi with mutations in cya, crp and cdt, Method of maintaining a desired recombinant gene in a genetic population of cells, Avirulent Salmonella containing genes encoding gamete specific antigen useful as vaccine for diminishing or preventing fertility, Method of vaccination of newly hatched poultry, Recombinant vaccines comprising immunogenic attenuated bacteria having RpoS  phenotype, Methods of producing and using virulence attenuated poxRmutant bacteria, Recombinant bacterial system with environmentally limited viability, Live attenuated Salmonella vaccines to control avian pathogens, Regulated Antigen Delivery Systems, and, various patents for Avirulent microbes.

Field of Use
The field of use Area means research, development and commercialization with respect to animal vaccines and therapeutic agent as further described in the Research Plan.

IPSCIO Record ID: 248399

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive license to use the Vaccine IP to further develop, manufacture, use, keep, import, export, supply or offer to supply, or, have a Partner manufacture, use, keep, import, export, supply or offer to supply, Plague Vaccine Doses to customers in performance of Supply Contracts.
License Property
Recombinant Yersinnia Pestis F1 and V (Plague) Protective Antigen Vaccine.

Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.

Patents are for Plague vacclnes and Vaccine Compositions.

Field of Use
The use in the United States is for the further development manufacture and supply of recombinant protective antigen plague vaccine doses.

The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.

IPSCIO Record ID: 248395

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products.
License Property
The Intellectual Property shall mean the Patents and knowhow, technical information and materials, including but not limited to cell lines, owned by the Licensor necessary or useful to develop, manufacture, have manufactured, import use, keep, sell and offer to sell the Plague Antigen and/or Vaccine.

Licensed Product shall mean a Plague Antigen, and/or a Vaccine including but not limited to a Plague Vaccine Dose, the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

Plague Antigen shall mean individually each of the F1 antigen and V antigen of Yesinnia Pestis.

Plague Vaccine Dose shall mean the quantity of Vaccine given to an individual in a single dose.

Patents are for Plague Vaccines and Vaccine Compositions.

Field of Use
The field of use for any UK Government purpose or otherwise to the extent customary pursuant to standard UK Ministry of Defense contracting procedures.

IPSCIO Record ID: 233440

License Grant
Licensor grants an exclusive, world-wide license, including the right to grant sublicenses, to manufacture, use, sell, offer for sale and import Products under all Licensors right, title and interest in the Patent Rights.
License Property
Licensor has developed coccidiosis vaccines and has filed patents for such vaccines, for the production and use in animals.

Coccidiosis is a parasitic disease of the avian digestive system, affecting feed intake, and therefore weight gain of the broiler bird.

The Vaccine Technology shall mean all technology, technical information, know how and expertise with respect to in ova-delivered live vaccines for, the control and/or prevention of coccidiosis in poultry that Licensor delivers or has previously delivered under the Research Agreement to Licensee in order to enable Licensee to practice the Patent Rights or enhance such practice.

The Vaccine Materials shall mean the Licensors materials including Eimeria strains.

The patents are for:  in ova vaccination with sporozoites and/or merozoites; and, in ova vaccination with oocysts and/or sporocysts; and,  method for purification, recovery, and sporulation of cysts and oocysts.

Field of Use
The vaccines are for the production and use in animals.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 248394

License Grant
The Licensor, government organization of England, grants the Licensee of England a nonexclusive worldwide license to use the Intellectual Property to develop, make, or have made, use, keep, sell, offer to sell, import and export Licensed Products, and to develop, make, have made, and use Anthrax Vaccine for the purpose of Licensor exercising the rights and licenses granted to Licensor with respect to Licensed Product.
License Property
Anthrax Vaccine shall mean protective antigen from Bacillus anthracis (anthrax) which is produced using recombinant technology.

Anthrax Vaccine Dose shall mean the quantity of a formulation containing Anthrax Vaccine given to an individual in a single immunization.

Licensed Product shall mean an Anthrax Vaccine Dose the manufacture, use, sale, keeping, importing or exporting of which would, in the absence of the license granted under this Agreement, constitute an infringement of the Patents or that uses other Intellectual Property.

The patent is for Expression System (Anthrax Immuuogenic Polypeptide), a UK Priority Patent Application.

Recombinant Bacillus Anthracis (Anthrax) Protective Antigen Vaccine containing Alum

The patent covers MOD Case P1454 Expression System.

Field of Use
These agreements allow for the licensing of certain patents and technology necessary to perform development of the rPA and rYP programs as required under the Company’s government contracts with the NIAID.

PharmAthene is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

IPSCIO Record ID: 233439

License Grant
The Swiss Licensor grants a non-exclusive license under the adr-HBsAg Technology, with the right to sublicense, to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories for use solely in the Disease Field. Such license grant does not permit the transfer by Licensee to any third party of adr-HBsAg other than as part of assembled
Vaccines, including, without limitation, transfer of Vaccines to third parties for preclinical testing, toxicology, or clinical trials, without the prior written approval of Berna, such approval not to be unreasonably withheld.  The license granted is specific to the Disease Field.

Licensor grants the right to sublicense the right to research, develop, manufacture, have manufactured, market, distribute, import, use, offer for sale and sell Vaccines in the Territories under the adr-HBsAg Technology in the Disease Field.

License Property
adr-HBsAg shall mean the hepatitis B surface antigen of the subtype adr produced with the Hansenula polymorpha Expression System.

Therapeutic Vaccine shall mean a therapeutic hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilises additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Prophylactic Vaccine shall mean a prophylactic Hepatitis B vaccine developed by Licensee or its sublicensee and comprised of an ISS and adr-HBsAg, and that potentially utilizes additional delivery or adjuvant technology, in pharmaceutical dosage forms suitable for human use.

Field of Use
Disease Field shall mean the field of inducing an active, long term prophylactic response or therapeutic immune response against Hepatitis B, including chronic status, in humans.

IPSCIO Record ID: 233458

License Grant
This amendment updates the grant, royalties, patents, and products.

The grant is replaced in its entirety with:
The University grants to Licensee exclusive licenses under Patent Rights to make, use, sell, offer for sale, and import Patent Products and Vaccine Adjuvant Product and to practice the Patent Method. Licensee is expressly prohibited from selling a Derived Product or Vaccine Adjuvant Product to any third party, except that Licensee may sell a Vaccine Adjuvant Product to the Third Party.

The University also grants to Licensee the right to issue sublicenses to third parties to make, use, sell, offer for sale, and import Patent Products and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.

The University also grants to Licensee the right to issue sublicenses to the Third Party to make, use, sell, offer for sale, and import Vaccine Adjuvant product and practice the Patent Method, provided Licensee retains current exclusive rights under this Agreement.

License Property
With this amendment:
The patents include Biologically Active Composition Having A Nanocrystalline Core; Human Immunodeficiency Virus Decoy; and, Targeted Transfection Nanoparticles.

The Drug Delivery Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for the use in pharmaceutical preparations to facilitate the therapeutic delivery of drugs in humans.

Vaccine Adjuvant Product means a Licensed Product that, when added as part of a Vaccine Product, improves the immune response so that less of a Vaccine Product is needed to produce more antibodies.

Vaccine Product means a Licensed Product, which would, were it used or sold in the United States, require marketing approval by an appropriate regulatory agency for any preparation containing a suspension of dead, attenuated, or otherwise modified microorganisms, e.g. viruses, bacteria, or rickettsiae, or parts thereof, that is used to produce an immunity against a disease in humans or other animals by stimulating the production of antibodies.

Derived Product means any product that is made by using a composition of matter claimed under Patent Rights or by practicing the Patent Method to make a final product regardless of the number of steps in the process or the number and types of compositions of matter, e.g., intermediate compounds, that are involved in making the final product. A Derived Product also means any product that is made by using a composition of matter claimed under Patent Rights whether or not that composition of matter is directly incorporated or a part of the final product.

Field of Use
Licensed Products means:
– a kit, composition of matter, material, product, or Derived Product;
– a kit, composition of matter, material, product, or Derived Product to be used in a manner requiring the performance of the Patent Method; or
– a kit, composition of matter, material, product, or Derived Product produced by the Patent Method;

The Excluded Field means any field other than a Vaccine Product, Drug Delivery Product, and Vaccine Adjuvant Product.

Patents are in fields of use initially pertaining to: (1) vaccine adjuvants; (2) vaccine constructs or combinations for use in immunization against herpes virus; (3) drug delivery systems; and (4) red blood cell surrogates.

IPSCIO Record ID: 279362

License Grant
The parties have agreed to enter an agreement for the Licensor of the United Kingdom to manufacture and supply products in the field of live or dead wild type attenuated or recombinant Listeria based vaccines to Licensee to undertake clinical trials and commercial sales in respect of such vaccines.

If Licensor is unwilling, or unable to supply and manufacture either Clinical Product or Bulk Product under the terms herein, Licensor will transfer the necessary Vaccine Process to enable a third party to manufacture and supply any part of the Clinical Product and/or Bulk Product to Licensee.

The parties have agreed that Licensor will have the right of first refusal to manufacture and supply Clinical Product and Bulk Product for use in the program of research and development, clinical trials and commercial exploitation.

License Property
Bulk Product means any and all Bulk Drug Substance, Drug Product and/or Programme Deliverable supplied by Licensor to Licensee under this Agreement for commercial use.

Clinical Product means the Programme Deliverable which is to be used in the development phase of the Programme and/or the Clinical Trials.

Vaccine Process means the process, methods, synthesis for making, using or exploiting the Drug Substance to produce the Drug Product for inclusion within the Programme Deliverable; .

Field of Use
The field of use is the field of live or dead cell based wild type or attenuated or recombinant Listeria vaccines with a therapeutic and/or preventative effect, for use in cancer and other indications.

IPSCIO Record ID: 237242

License Grant
Each of the Parties agree to perform the work designated in the Work Plan and Budget to be performed by it, respectively, in the course of the Research and Development Program substantially within the time frames designated in the Work Plan and Budget.  Licensee will act as the primary Vaccine Developer under the Work Plan and Budget. Licensor and Licensee will be entitled to involve one or more subcontractors in the performance of such work, provided that each such subcontractor is approved in writing for such purpose by all parties to this Agreement, which approval shall not be unreasonably withheld or delayed. Licensor acknowledges that later steps and phases of work in the Research and Development Program, and the time frames therefor, will depend in part upon the results achieved in earlier steps and phases. The responsibility of Licensor and Licensee hereunder shall be satisfied by their devotion to the Research and Development Program of the efforts called for from them, respectively, in the Work Plan and Budget; neither of Licensor nor Licensee warrants or commits that it will achieve successful or timely results in the conduct of the Research and Development Program.
License Property
Program Inventions shall mean inventions, discoveries, and improvements, patentable or unpatentable, first conceived or reduced to practice by Licensor, Licensee, Licensor, or the subcontractors of any of them during and in the course of work under the Research and Development Program, inclusive of any cell lines or other materials first developed in the course of such work under the Research and Development Program.

Licensee-Controlled Inventions shall mean the inventions disclosed in the United States patents and foreign equivalents and United States and foreign patent applications listed and all divisions, continuations, continuations in part, reissues, or extensions thereof, any periods of marketing exclusivity relating thereto, and any letters patent that issue thereon. It is understood that certain of the Licensee-Controlled Inventions (the Licensed Licensor Rights) are owned by Licensor and are covered by one or more exclusive licenses or sublicenses to Licensee, directly or indirectly.

US 5,858,775 – Adeno-associated virus materials and methods
US 5,786,211 – Adeno-associated virus materials and methods
US 5,658,785 – Adeno-associated virus materials and methods
US 5,139,941 – AAV transduction vectors

Program Vaccines shall mean any AAV (adeno-associated virus) particle-based vector that contains an HIV-1 gene in the recombinant vector genome and that can act as a prophylactic vaccine against HIV-1.

Proprietary Technology shall mean any Background Technology to the extent it has not previously been disclosed in an issued patent or a published patent application. Background Technology shall mean: (i) the rights to make, use, sell, offer for sale, and import the Licensee-Controlled Inventions; (ii) all inventions (whether or not patented or patentable), know-how, techniques, cell lines, data, studies and results of studies and other proprietary information in the possession or control of Licensor at the Effective Date and at any time thereafter during the period in which Licensor remains a direct participant in the Research and Development Program, to the extent bearing upon the Program Vaccines, the Licensee-Controlled Inventions, the Program Inventions, or any of them within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensor); and (iii) know-how and other proprietary information in the possession or control of Licensee at the Effective Date and at any time thereafter during the period in which Licensee remains a direct participant in the Research and Development Program, to the extent useful for the practice of the Licensee-Controlled Inventions within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensee).

Work Plan and Budget shall mean the set of tasks, procedures, protocols, standards, budgets, and target time frames set forth, as such may be amended or supplemented by mutual written agreement of the parties from time to time.

Field of Use
This agreement pertains to the drug industry primarily relating to vaccine development.

Program Field shall mean the manufacture of one or more of the Program Vaccines through the use of the particular combination of Program Inventions and Background Technology as implemented by Licensor and Licensee under this Agreement during and in the course of the Research and Development Program (as the same may be supplemented or improved by or for Licensor with other inventions or technology from sources other than Licensor or Licensee), solely for distribution in the Public Sector, and the use, sale, offer for sale, and import of such Program Vaccines so manufactured in and to the Public Sector. I

The collaboration agreement is to develop a vaccine to prevent AIDS. The vaccine will utilize Targeted Genetics’ Adeno-Associated  Viral Vectors (AAV ) to deliver HIV genes as a novel form of genetic immunization.

IPSCIO Record ID: 280952

License Grant
Licensor grants to the Licensee of Barbados a world-wide, non-exclusive license, with the right to sublicense, under the Licensed Patents and Know-How, to utilize Licensed Adjuvant in connection with the manufacture, sale, offer for sale, importation and use of any Product in the Field of Use for the Term; and a worldwide, nonexclusive license, with the right to sublicense, under the Licensed Patents and Know-How to manufacture Licensed Adjuvant solely for use in the manufacture of Products for sale, offer for sale, importation and use in the Field of Use.

For the Research Licenses, Licensor grants a world-wide, non-exclusive license, with the right to sublicense, under the Licensed Patents and Know-How, to use and import Licensed Adjuvant solely to conduct research for, or in respect of, the development of Products for use in the Field of Use for the Term.

Licensor grants the right to sublicense the rights granted herein.

For the Trademark License, Licensor grants a worldwide, royalty-free, nontransferable, non-exclusive license, during the term, to use and reproduce the Powered by Corixa trademark in the course of distributing, promoting and selling the Products solely for use within the Field of Use in the Territory.

License Property
Licensor owns intellectual property rights in immunostimulatory material known as MPL, which is a potentially useful component of vaccines to treat various diseases.

Product means any pharmaceutical composition, comprising the Licensees Antigen and Licensed Adjuvant as an ingredient or component.

Licensees Antigen, BLP25 MUCl antigen, as such antigen may be improved, enhanced, or otherwise modified, as well as any other antigens that incorporate MUC 1.

Field of Use
Field of Use shall mean the treatment of cancer in humans and companion animals.

IPSCIO Record ID: 227256

License Grant
Licensee hereby grants to Licensee a non-exclusive, worldwide, sublicensable, royalty-bearing license in the Field under the Patent Rights and Know-How Technology to use said Pfénex Expression Technology™ to make, have made, use and sell Product for clinical and commercial use. Licensee shall not have any right to sublicense its rights under this Agreement other than to Affiliates,
License Property
Pfénex Expression Technology™ shall mean Patent Rights and Know-How Technology related to or using directly or indirectly the Biological Material, Pseudomonas bacterial strains, DNA, components and vectors for the expression of foreign proteins and Active.

Patent Rights shall mean Licensor owned or controlled patent applications U.S. Serial Nos. 60/523,420 and 2005/001,549 and any divisional, continuation, foreign equivalent, substitute, renewal, extension, reissue, reexamination, patents of addition, supplemental protection certificate, or application therefore or patent issuing therefrom.

Product shall mean any product or combination product containing Active where the manufacture or formulation of such Active (i) would (but for the license granted hereunder) infringe any Valid Claim of any Patent Right or (ii) involved the practice of Know-How Technology.

Field of Use
Field shall mean use in human vaccines for the prevention of diseases caused by  pathogenic microorganisms and use for therapeutic applications or therapeutic vaccines or in combination with one or more autoantigens.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.